Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2009, Pages 609-614

  Kim, Kyoung Ah ^a   Park, Pil Whan ^b   Park, Ji Young ^a  

^a Korea University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Drug interaction; Fexofenadine; P glycoprotein; Quercetin

Indexed keywords

DRUG DERIVATIVE; FEXOFENADINE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; QUERCETIN; TERFENADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLISM; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SPECTROFLUOROMETRY;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; P-GLYCOPROTEIN; QUERCETIN; REFERENCE VALUES; SPECTROMETRY, FLUORESCENCE; TERFENADINE;

EID: 68849107630     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-009-0627-6     Document Type: Article

References (34)

1. Middleton E Jr (1998) Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 439:175-182
2. Formica JV, Regelson W (1995) Review of the biology of quercetin and related bioflavonoids. Food Chem Toxicol 33 (12):1061-1080 (Pubitemid 26009773)
3. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L (2004) Polyphenols: food sources and bioavailability. Am J Clin Nutr 79 (5):727-747 (Pubitemid 41103873)
4. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, Piantelli M, Bussa S, Rumi C, Cianfriglia M et al (1994) Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 34(6):459-464 (Pubitemid 24306043)
5. Kim SH, Yeo GS, Lim YS, Kang CD, Kim CM, Chung BS (1998) Suppression of multidrug resistance via inhibition of heat shock factor by quercetin in MDR cells. Exp Mol Med 30(2):87-92
6. Shapiro AB, Corder AB, Ling V (1997) P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 250(1):115-121 (Pubitemid 27504590)
7. Eagling VA, Profit L, Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48(4):543-552 (Pubitemid 29454235)
8. Choi JS, Li X (2005) Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits. Int J Pharm 297(1-2):1-8
9. Wang YH, Chao PD, Hsiu SL, Wen KC, Hou YC (2004) Lethal quercetin-digoxin interaction in pigs. Life Sci 74(10):1191-1197
10. Simpson K, Jarvis B (2000) Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59(2):301-321 (Pubitemid 30168518)
11. Markham A, Wagstaff AJ (1998) Fexofenadine. Drugs 55(2):269-274 discussion 275-266
12. Kamisako T, Adachi Y, Nakagawa H, Yamamoto T (1995) Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 34(2):92-95
13. Ling KH, Leeson GA, Burmaster SD, Hook RH, Reith MK, Cheng LK (1995) Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 23(6):631-636
14. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, Sugiyama Y (2006) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34(5):743-747
15. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27 (8):866-871 (Pubitemid 29347585)
16. Perloff MD, von Moltke LL, Greenblatt DJ (2002) Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 42(11):1269-1274 (Pubitemid 35205064)
17. Kim KA, Park PW, Kim HK, Ha JM, Park JY (2005) Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol 45(8):941-946
18. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG (2005) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther 78(2):191-201
19. Uno T, Shimizu M, Sugawara K, Tateishi T (2006) Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos 34(11):1875-1879 (Pubitemid 44771716)
20. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, Cameron DW (2006) Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46 (7):758-767 (Pubitemid 43882799)
21. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD (2002) Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71(6):414-420 (Pubitemid 34701348)
22. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69(3):114-121 (Pubitemid 32225411)
23. Choi JS, Choi BC, Choi KE (2004) Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health Syst Pharm 61(22):2406-2409 (Pubitemid 40403583)
24. Patel J, Buddha B, Dey S, Pal D, Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11(4):262-277
25. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68(6):598-604 (Pubitemid 32059985)
26. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H, Sawada Y (2000) Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 395 (3):193-201 (Pubitemid 30254368)
27. Kim KA, Park JY, Lee JS, Lim S (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26(8):631-637
28. Kim KA, Chung J, Jung DH, Park JY (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60(8):575-581 (Pubitemid 39517911)
29. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF (1993) Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 36(5):460-463 (Pubitemid 23344157)
30. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308(2):438-445 (Pubitemid 38134202)
31. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71(1):11-20 (Pubitemid 34124034)
32. Dresser GK, Kim RB, Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77(3):170-177 (Pubitemid 40269132)
33. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF (2005) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59(5):602-604 (Pubitemid 40632253)
34. Wang X, Wolkoff AW, Morris ME (2005) Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33(11):1666-1672 (Pubitemid 41539965)